Journal of Affective Disorders
Volume 65, Issue 2 , Pages 105-115 , July 2001

Drug abuse and bipolar disorder: comorbidity or misdiagnosis?

  • E Sherwood Brown

      Affiliations

    • Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9070, USA
    • Corresponding Author InformationCorresponding author
    • ,
  • Trisha Suppes

      Affiliations

    • Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9070, USA
    • ,
  • Bryon Adinoff

      Affiliations

    • Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9070, USA
    • Psychiatry Service, Dallas Veterans Affairs Medical Center, Dallas, TX, USA
    • ,
  • Nancy Rajan Thomas

      Affiliations

    • Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9070, USA

Received 29 January 1999 ,Accepted 10 December 1999.

References 

  1. Aagaard J, Vestergaard P. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J. Affect. Disord. 1989;12:259–266
  2. Akiskal HS, Djenderedijian AH, Rosenthal RH, Khani MK. Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am. J. Psychiatry. 1977;134:1227–1233
  3. Akiskal HS, Downs J, Jordan P, Watson S, Daugherty D, Pruitt DB. Affective disorders in referred children and younger siblings of manic-depressives: mode of onset and prospective course. Arch. Gen. Psychiatry. 1985;42:996–1003
  4. Albanase MJ, Khantzian EJ, Murphy SL. Decreased substance use in chronically psychotic patients treated with clozapine. Am. J. Psychiatry. 1994;151:780–781Letter
  5. Arana GW, Baldessarini RJ, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Arch. Gen. Psychiatry. 1985;42:1193–1204
  6. Bauer MS, Shea N, McBride L, Gavin C. Predictors of service utilization in veterans with bipolar disorder: a prospective study. J. Affect. Disord. 1997;44:159–168
  7. Baumann MH, Gendro TM, Becketts KM, Heningfield JE, Gorelick DA, Rothman RB. Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers. Biol. Psychiatry. 1995;38:751–755
  8. Brady K, Casto S, Lydiard RB, Lalcolm R, Arana G. Substance abuse in an inpatient psychiatric sample. Am. J. Drug Alcohol Abuse. 1991;17:389–397
  9. Brady KT, Sonne SC. The relationship between substance abuse and bipolar disorder. J. Clin. Psychiatry. 1995;56:19–24
  10. Brady KT, Sonne SC, Anton R, Ballenger JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J. Clin. Psychiatry. 1995;56:118–121
  11. Brady KT, Sonne SC, Dansky BS, Roberts JC, Malcolm RJ. Carbamazepine in cocaine-dependent individuals with affective disorder. In: College on Problems of Drug Dependence Annual Meeting, Scottsdale, AZ. 1998;
  12. Bradley CJ, Zarkin GA. Inpatient stays for patients diagnosed with severe psychiatric disorders and substance abuse. Health Serv. Res. 1996;31:339–408
  13. Britton DR, Curzon P, Mackenzie RG, Kebabian JW, Williams JEB, Kerkman D. Evidence for involvement of both D1 and D2 receptors in maintaining cocaine self-administration. Pharmacol. Biochem. Behav. 1991;39:911–915
  14. Brooner RK, King VL, Kidord M, Schmidt CW, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch. Gen. Psychiatry. 1997;54:71–80
  15. Brown SA, Inaba RK, Gillin JC, Schuckit MA, Stewart BA, Irwin MR. Alcoholism and affective disorder: clinical course of depressive symptoms. Am. J. Psychiatry. 1995;152:45–52
  16. Buckley PF. Substance abuse in schizophrenia: a review. J. Clin. Psychiatry. 1998;59:26–30
  17. Chen YR, Swann AC, Johnson BA. Stability of diagnosis in bipolar disorder. J. Nerv. Ment. Dis. 1998;186:17–23
  18. Corrigall WA, Coen KM. Cocaine self-administration is increased by both D1 and D2 dopamine antagonists. Pharmacol. Biochem. Behav. 1991;39:799–802
  19. de la Garza R, Johanson CE. Effects of haloperidol and physostigmine on self-administration of local anesthetics. Pharmacol. Biochem. Behav. 1982;17:1295–1299
  20. D’Mello DA, Boltz MK, Msibi B. Relationship between concurrent substance abuse in psychiatric patients and neuroleptic dosage. Am. J. Drug Alcohol Abuse. 1995;21:257–265
  21. Dell’Osso L, Akiskal HS, Freer P, Barberi M, Placidi GF, Cassano GB. Psychotic and nonpsychotic bipolar mixed states: comparisons with manic and schizoaffective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 1993;243:75–81
  22. Deroche V, Marinelli M, Maccari S, Moal ML, Simon H, Piazza PV. Stress-induced sensitization and glucocorticoids I. Sensitization of dopamine-dependent locomotor effects of amphetamine and morphine depends on stress-induced corticosterone secretion. J. Neurosci. 1995;15:7181–7188
  23. Dunner DL, Hensel BM, Fieve RR. Bipolar illness: factors in drinking behavior. Am. J. Psychiatry. 1979;136:583–585
  24. Estroff TW, Dackis CA, Gold MS, Pottash ALC. Drug abuse and bipolar disorders. Int. J. Psychiatry Med. 1985;15:37–40
  25. Ettenberg A, Pettit HO, Bloom FE, Koob GF. Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. Psychopharmacol. (Berl.). 1982;78:204–209
  26. Feinman JA, Dunner DL. The effect of alcohol and substance abuse on the course of bipolar affective disorder. J. Affect. Disord. 1996;37:43–49
  27. Forman LJ, Estilow S. Cocaine influences beta-endorphin levels and release. Life Sci. 1988;43:309–315
  28. Freed EX. Alcohol abuse by manic patients. Psychol. Rep. 1969;25:280
  29. Gawin FH, Kleber HD. Cocaine abuse treatment: open pilot trial with desipramine and lithium carbonate. Arch. Gen. Psychiatry. 1984;41:903–909
  30. Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Arch. Gen. Psychiatry. 1986;43:107–113
  31. Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J. Am. Acad. Child Adolesc. Psychiatry. 1998;37:171–178
  32. Goeders NE. A neuroendocrine role in cocaine reinforcement. Psychoneuroendocrinology. 1997;22:237–259
  33. Goeders NE, Guerin GF. Role for corticosterone in intravenous cocaine self-administration in rats. Neuroendocrinology. 1996;64:337–348
  34. Goodwin FK, Jamison KR. Alcohol and drug abuse in manic-depressive illness. In: Manic-Depressive Illness. Oxford; 1990;p. 210–226Chapter 9
  35. Haywood TW, Karvitz HM, Grossman LS, Cavanaugh JL, Davis JM, Lewis DA. Predicting the ‘Revolving Door’ phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am. J. Psychiatry. 1995;152:856–861
  36. Heesch CM, Negus BH, Keffer JH, Snyder RW, Risser RC, Eichorn EJ. Effects of cocaine on cortisol secretion in humans. Am. J. Med. Sci. 1995;320:61–64
  37. Himmelhoch JM, Garfinkel M. Sources of lithium resistance in mixed mania. Psychopharmacol. Bull. 1986;22:613–620
  38. Himmelhoch JM, Mulla D, Neil JF, Detre TP, Kupfer JD. Incidence and significance of mixed affective states in a bipolar population. Arch. Gen. Psychiatry. 1976;33:1062–1066
  39. Johanson CE, Kandel D, Bonese KF. The effects of perphenazine on self-administration behavior. Pharmacol. Biochem. Behav. 1976;4:427–433
  40. Keck PE, McElroy SL, Strakowski SM, Balistreri TM, Kizer DJ, West SA. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J. Clin. Psychol. 1996;57:147–151
  41. Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am. J. Orthopsychiatry. 1996;66:17–31
  42. Koob GF, Le HT, Creese I. D-1 receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neurosci. Lett. 1987;79:315–321
  43. Kosten TR, Nestler EJ. Clozapine attenuates cocaine conditioned place preference. Life Sci. 1994;55:PL9–14
  44. Krauthammer C, Klerman GL. Secondary mania: manic syndromes associated with antecedent physical illness or drugs. Arch. Gen. Psychiatry. 1978;35:1333–1339
  45. Lambert MT, Griffith JM, Hendrickse W. Characteristics of patients with substance abuse diagnoses on a general psychiatry unit in a VA medical center. Psychiatr. Serv. 1996;47:1104–1107
  46. LeDuc PA, Mittleman G. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology. 1995;12:407–427
  47. Levy AD, Li Q, Kerr JE, Rittenhouse PA, Milonas G, Cabrera TM, et al. Cocaine-induced elevation of plasma adrenocorticotropic hormone and corticosterone is medicated by serotonergic neurons. J. Pharmacol. Exp. Ther. 1991;259:495–500
  48. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine. Am. J. Psychiatry. 1995;152:959;Letter
  49. Marken PA, Stanislav SW, Lacombe S, Pierce C, Horstra R, Sommi RW. Profile of a sample of subjects admitted to an acute care psychiatric facility with manic symptoms. Psychopharmacol. Bull. 1992;28:201–205
  50. Martin-Iverson MT, Szostak C, Fibiger HC. 6-Hydroxydopamine lesions of the medial prefrontal cortex fail to influence intravenous self-administration of cocaine. Psychopharmacol. (Berl.). 1986;88:310–324
  51. McElroy SL, Keck PE, Pope HG, Hudson JL, Faedda GL, Swann AC, et al. Hypothalamic-pituitary-adrenocortical function in mixed and pure mania. Acta Psychiatr. Scand. 1992;85:270–274
  52. McElroy SL, Strakowski SM, West SA, Keck PE, McConville BJ. Phenomenology of adolescent and adult mania in hospitalized patients with bipolar disorder. Am. J. Psychiatry. 1997;1541:44–49
  53. Mendelson JH, Mello NK, Teoh SK, Ellingboe J, Cochin J. Cocaine effects on pulsatile secretion of anterior pituitary gonadal, and adrenal hormones. J. Clin. Endocrinol. Metab. 1989;69:1256–1260
  54. Mendelson JH, Teoh SK, Mello NK, Ellingboe J. Bupronorphine attenuates the effects of cocaine on adrenocorticotropin (ACTH) secretion and mood states in man. Neuropsychopharmacology. 1992;7:157–162
  55. Mendlewicz J, Fieve RR, Rainer JD, Fleiss JL. Manic-depressive illness: a comparative study of patients with and without a family history. Am. J. Psychiatr. 1972;120:523–530
  56. Miller FT, Busch F, Tanenbaum JH. Drug abuse in schizophrenia and bipolar disorder. Am. J. Drug Alcohol Abuse. 1989;15:291–295
  57. Moldow RL, Fischman AJ. Cocaine induced secretion of ACTH, beta-endorphin, and corticosterone. Peptides. 1987;8:819–822
  58. Morrison JR. Bipolar affective and alcoholism. Am. J. Psychiatry. 1974;131:1130–1133
  59. Mueser KT, Yarnold PR, Bellack AS. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatr. Scand. 1992;85:48–55
  60. Nunes EV, Quitkin FM, Klein DF. Psychiatric diagnosis in cocaine abuse. Psychiatr. Res. 1989;28:105–114
  61. Nunes EV, McGrath PJ, Wager S, Quitkin FM. Lithium treatment for cocaine abusers with bipolar spectrum disorders. Am. J. Psychiatry. 1990;147:655–657
  62. O’Connell R, Mayo J, Flatow L, Cuthbertson B, O’Brien B. Outcome of bipolar disorder on long-term treatment with lithium. Br. J. Psychiatry. 1991;159:123–129
  63. O’Croinin F, Zibin T, Byrne A. Life events and relapse in bipolar disorder. Br. J. Psychiatry. 1994;164:417;Letter
  64. Peet M, Peters S. Drug-induced mania. Drug Safety. 1995;12:146–153
  65. Piazza PV, Maccari S, Deminière JM, LeMoal M, Mormède P, Simon H. Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc. Natl. Acad. Sci. USA. 1991;88:2088–2092
  66. Piazza PV, Deroche V, Deminière JM, Maccari S, LeMoal M, Simon H. Corticosterone in the range of stress-induced levels possesses reinforcing properties: implications for sensation-seeking behaviors. Proc. Natl. Acad. Sci. USA. 1993;90:11738–11742
  67. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. J. Am. Med. Assoc. 1990;264:2511–2518
  68. Risner ME, Jones BE. Role of noradrenergic and dopaminergic processes in amphetamine self-administration. Pharmacol. Biochem. Behav. 1976;5:477–482
  69. Roberts DCS, Vickers G. Atypical neuroleptics increase self-administration of cocaine: an valuation of a behavioral screen for antipsychotic activity. Psychopharmacol. (Berl.). 1984;82:135–139
  70. Roberts DCS, Vickers G. The effect of haloperidol on cocaine self-administration is augmented with repeated administrations. Psychopharmacology. 1987;293:526–528
  71. Rounsaville BJ, Anton SF, Carroll K, Budde D, Prusoff BA, Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch. Gen. Psychiatry. 1991;48:43–51
  72. Saphier D, Welch JE, Farrar GE, Goeders NE. Effects of intracerebro-ventricular and intrahypothalamic cocaine administration on adrenocortical secretion. Neuroendocrinology. 1993;57:54–62
  73. Satija DC, Sharma DK, Gaur A, Nathawat SS. Prognostic significance of psychopathology in the abstinence from opiate addiction. Indian J. Psychiatr. 1989;31:157–162
  74. Saxon AJ, Calsyn DA, Stanton V, Hawker CS. Using the general behavior inventory to screen for mood disorders among patients with psychoactive substance dependence. Am. J. Addict. 1994;3:296–305
  75. Schatzberg AF. Bipolar disorder: recent issues in diagnosis and classification. J. Clin. Psychiatry. 1998;59:5–10
  76. Schuckit MA. Alcohol and depression: a clinical perspective. Acta Psychiatr. Scand. 1994;89:28–32
  77. Schuckit MA, Tipp JE, Bergman M, Reich W. Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Am. J. Psychiatry. 1997;154:948–957
  78. Scott H, Johnson S, Menezes P, Thornicroft G, Marshall J, Bindman J, et al. Substance misuse and risk of aggression and offending among the severely mentally ill. Br. J. Psychiatry. 1998;172:345–350
  79. Sernyak MJ, Godleski LS, Griffin RA, Mazure CM, Woods SC. Chronic neuroleptic exposure in bipolar outpatients. J. Clin. Psychiatry. 1997;58:193–195
  80. Sonne SC, Brady KT, Morton WA. Substance abuse and bipolar affective disorder. J. Nerv. Ment. Dis. 1994;182:349–352
  81. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Goodwin DC. Comorbidity in mania at first hospitalization. Am. J. Psychiatry. 1992;149:554–556
  82. Strakowski SM, McElroy SL, Keck PE, West SA. The effects of antecedent substance abuse on the development of first-episode psychotic mania. J. Psychiatr. Res. 1996;30:59–68
  83. Suppes T, Leverich GS, Keck PE, Nolen WA, Denicoff KD, Altshuler LL, et al. The Stanley Foundation Bipolar Treatment Outcome Network: II. Demographics and illness characteristics of the first 261 patients. J. Affect. Disord. 2000;in press
  84. Swann AC. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania. Am. J. Psychiatry. 1992;149:1633–1644
  85. Swann AC. Manic-depressive illness and substance abuse. Psychiatr. Ann. 1997;27:507–511
  86. Todd RD, Geller B, Neuman R, Fox LW, Kickok J. Increased prevalence of alcoholism in relatives of depressed and bipolar children. J. Am. Acad. Child Adolesc. Psychiatry. 1996;35:716–724
  87. Tohen M, Waternaux C, Tsuang M. Outcome in mania, a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch. Gen. Psychiatry. 1990;47:1106–1111
  88. Tsuang JW, Eckman TE, Shaner A, Marder SR. Clozapine for substance-abusing schizophrenic patients. Am. J. Psychiatry. 1999;156:1119–1120Letter
  89. Vanover KE, Piercey MF, Woolverton WL. Evaluation of the reinforcing and discriminative stimulus effects of cocaine in combination with (+)AJ76 or clozapine. J. Pharmacol. Exp. Ther. 1993;266:789
  90. Vollenweider FX, Maguire RP, Leenders KL, Mathys K, Angst J. Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Res. 1998;83:149–162
  91. Warner R, Taylor D, Wright J, Sloat A, Springett G, Arnold S, et al. Substance use among the mentally ill: prevalence, reasons for use, and effects on illness. Am. J. Orthopsychiatry. 1994;64:30–39
  92. Weiss RD, Mirin SM, Griffin ML, Michael JL. Psychopathology in cocaine abusers. J. Nerv. Ment. Dis. 1988;176:719–725
  93. Weiss RD, Greenfield SF, Najavits LM, Soto JA, Wyner D, Tohen M, et al. Medication compliance among patients with bipolar disorder and substance use disorder. J. Clin. Psychiatry. 1998;59:172–174
  94. Wilens TE, Biederman J, Abrantes AM, Spencer TJ. Clinical characteristics of psychiatrically referred adolescent outpatients with substance use disorder. J. Am. Acad. Child Adolesc. Psychiatry. 1997;36:941–947
  95. Wilson MC, Schuster CR. The effects of chlorpromazine on psychomotor stimulant self-administration in the rhesus monkey. Psychopharmacologia. 1972;26:115–126
  96. Winokur G, Coryell W, Endicott J, Keller M, Akiskal H, Solomon D. Familial alcoholism in manic-depressive (bipolar) disease. Am. J. Med. Genet. (Neuropsychiatr. Genet.). 1996;67:197–201
  97. Winokur G, Turvey C, Akiskal H, Coryell W, Solomon D, Leon A, et al. Alcoholism and drug abuse in three groups — bipolar I, unipolars and their acquaintances. J. Affect. Disord. 1998;50:81–89
  98. Woolverton WL. Effect of a D1 and a D2 dopamine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol. Biochem. Behav. 1986;24:531–535
  99. Yokel RA, Wise RA. Increased lever pressing for amphetamine after pimozide in rats: implication for a dopamine theory of reward. Science. 1975;187:547–549
  100. Yovell Y, Opler LA. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: a case report and a hypothesis. J. Nerv. Ment. Dis. 1994;182:591–592

PII: S0165-0327(00)00169-5

Journal of Affective Disorders
Volume 65, Issue 2 , Pages 105-115 , July 2001

Article Tools